Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
October 29, 2018
BrainStorm Announces Financial Results for the Third Quarter of 2018 and Provides a Corporate Update
BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today financial results for the third quarter and ...
October 29, 2018
Galmed Pharmaceuticals to Report Third Quarter 2018 Financial Results and Provide Business Update on Monday, November 5
TEL AVIV, Israel, Oct. 29, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver ...
October 29, 2018
Acer Therapeutics Submits NDA for EDSIVO™ for the Treatment of vEDS
NEWTON, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for ...
October 29, 2018
BioDelivery Sciences Announces Changes to its Executive Leadership Team
RALEIGH, N.C., Oct. 29, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic ...
October 29, 2018
Spring Bank Pharmaceuticals to Host R&D Day on Thursday, December 6, 2018
HOPKINTON, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral ...
October 24, 2018
Santhera Announces Start of Phase Ib/IIa Trial with POL6014 in Patients with Cystic Fibrosis
Pratteln, Switzerland, October 24, 2018 - Santhera Pharmaceuticals (SANN.SW) announces the start of a Phase Ib/IIa multiple ascending dose (MAD) trial with POL6014 in patients with ...
October 24, 2018
miRagen Therapeutics to Report Third Quarter 2018 Financial Results and Host Conference Call on November 7, 2018
BOULDER, Colo., Oct. 24, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, ...
October 24, 2018
Catalyst Biosciences Receives A Notice of Allowance from The Japan Patent Office Covering Modified Factor X Polypeptides
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology ...
October 24, 2018
RedHill Biopharma Announces Final Patient Assessed in Confirmatory Phase III Study with TALICIA® for H. pylori Infection
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 24, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty ...
October 24, 2018
Genkyotex Provides Corporate Update and Reports Cash Position at September 30, 2018
Genkyotex (GKTX.PA) (GKTX.PA) (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today provides a business update, including ...
October 23, 2018
iCAD Announces New Clinical Data on the Xoft Electronic Brachytherapy System for Early-Stage Breast Cancer Treatment Demonstrating Positive Results
NASHUA, N.H. and SAN ANTONIO, Oct. 23, 2018 (GLOBE NEWSWIRE) -- (Booth #3457) – iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection ...
October 23, 2018
HTG Molecular Diagnostics Announces the Institute of Oncology Research Has Adopted the HTG EdgeSeq Technology in its Genomics Facility
TUCSON, Ariz., Oct. 23, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM) (“HTG”), a provider of instruments, reagents, and services for molecular profiling applications, ...
October 23, 2018
Krystal Biotech Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Over-Allotment Option
PITTSBURGH, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (KRYS) (the “Company”), a gene therapy company dedicated to developing and commercializing novel treatments for ...
October 23, 2018
Neovasc Announces Successful Tiara™ "Live Case" at the 32nd Annual EACTS 2018 Meeting
VANCOUVER, Oct. 22, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement ...
October 23, 2018
Innate Pharma strengthens and expands its oncology development collaboration with AstraZeneca
Innate Pharma SA ("Innate" - Euronext Paris: FR0010331421 - IPH), today announced a new multi-term agreement with AstraZeneca, and its global biologics research and development ...
October 23, 2018
Aptose to Release Third Quarter Ended September 30, 2018 Financial Results on November 6, 2018
SAN DIEGO and TORONTO, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting ...
October 23, 2018
Newly Granted European Composition of Matter Patent Extends Exclusive Protection for VBL Therapeutics' Lead Drug Candidate VB-111 until October 2033
TEL AVIV, Israel, Oct. 23, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT), today announced the issuance by the European Patent Office (EPO) of Patent No. ...
October 23, 2018
BioDelivery Sciences to Report Third Quarter 2018 Financial Results on November 8, 2018
RALEIGH, N.C., Oct. 23, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients living ...
October 23, 2018
Vaccinex, Inc. to Participate on a Panel and Meet with Investors at the BTIG Healthcare Conference October 25, 2018
ROCHESTER, N.Y., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat ...
October 23, 2018
Zosano Treats over 4,000 Migraines and Reaches an Important Goal in M207-ADAM Long-term Safety Study
FREMONT, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that more than 150 ...
Page 10 of 117